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The complement fixation test (CFT) is a method tradi-
tionally used for diagnosis of gestational pemphigoid. Its 
performance in diagnosis of bullous pemphigoid (BP) 
has not been investigated in a large patient cohort. The 
aim of this single-centre, retrospective, serological case-
control study of 300 patients with BP and 136 control pa-
tients was to analyse its operating characteristics. CFT 
was found to have a sensitivity of 71.7% and a specificity 
of 100%. Furthermore, CFT diagnosed 20 of 46 patients 
with BP (43.5%) who were negative for both BP180 and 
BP230 enzyme-linked immunoassays (ELISAs), 31 of 
66 patients (47.0%) who were negative for indirect im-
munofluorescence of the oesophagus, 5 of 14 patients 
(35.7%) who were serologically negative for all investi-
gated serological assays, and 7 of 18 patients (38.9%) in 
whom direct immunofluorescence was negative. Combi-
nation of CFT with all other serological assays resulted 
in a sensitivity of 95.3%. In conclusion, CFT is suitable 
for the diagnosis of BP, and can help to diagnose serolo-
gically challenging cases. Key words: complement-fixing 
factor; herpes gestationis factor test; BP180; BP230; di-
rect immunofluorescence; indirect immunofluorescence; 
herpes gestationis.
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Bullous pemphigoid (BP) is the most common autoim-
mune bullous skin disorder in the elderly, its incidence 
has increased in the last decade in many countries, with 
estimated reported incidence rates between 2.5–42.8 and 
6.1–13.4 cases/million/year worldwide and in Germany, 
respectively (1–3). In BP, autoantibodies are produced 
against the hemidesmosomal antigens BP180 (BPAG2, 
collagen XVII) and BP230 (BPAG1), which play a role 
in the attachment of basal keratinocytes to the basement 
membrane (4). Diagnosis of BP is generally based on 
clinical picture, histology including direct immunofluo-
rescence (DIF), and detection of circulating autoantibo-
dies by indirect immunofluorescence (IIF) on monkey 
esophagus, salt-split human skin, as well as by BP180 
and BP230 enzyme-linked immunoassays (ELISAs) (4). 
In BP, all immunoglobulin G (IgG) subclasses have been 
shown to play a role (5). IgG1–3 are complement-fixing 
antibodies, but IgG4 cannot fix complement (6).
Single serological tests usually detect 60–80% of 
patients with BP (i.e. sensitivity = 60–80%) (4, 7–9). 
Only the combination of the assays yields a higher 
sensitivity; for instance, with the combination of 
BP180 and BP230 ELISA, a sensitivity of 85–91% 
can be achieved (8, 9 and unpublished data from 7). 
The relatively low sensitivity may be based on mild 
disease course or initially low amounts of circulating 
autoantibodies. Thus, serological tests with improved 
sensitivity and useful for a combination are needed. One 
such possibility could be the complement fixation test 
(CFT, also called the herpes gestationis factor test), in 
which the signal is enhanced by complement. 
CFT is commonly used for the diagnosis of pem-
phigoid gestationis (earlier termed herpes gestationis), 
which is immunopathogenetically closely related to BP, 
occurring during pregnancy or shortly thereafter (10). 
CFT is a special IIF method performed on healthy human 
salt-split skin tissue sections detecting complement C3 
fixed by IgG (11–15). Previous studies have documen-
ted its potential usefulness for diagnosis of BP (16, 17), 
but its performance has not been investigated in a large 
patient cohort. The aim of this study was therefore to eva-
luate the performance of CFT as a diagnostic test for BP.
MATERIALS AND METHODS
Patients 
This study was a single-centre, retrospective, serological 
case-control study with 300 patients with BP and 136 control 
patients. Serum samples were taken consecutively between 
November 2008 and December 2014 at the Department of 
Dermatology and Allergology, Ludwig Maximilian University, 
Munich. From patients with BP, only samples taken at the time 
of first diagnosis before introduction of any immunosuppressive 
therapy were included. Control sera were taken from patients 
with suspected bullous autoimmune skin disease in whom such 
a disease could be excluded. This type of retrospective, non-
interventional study on laboratory data, which were produced 
for routine diagnostic purposes, does not require ethics appro-
val in Germany. The diagnosis was based on clinical features 
together with at least 2 positive results of traditional histology, 
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DIF, IIF, BP180 or BP230 ELISA (for details, see reference 7). 
IIF was regarded as positive if IIF either monkey oesophagus, 
or rabbit oesophagus or salt-split human skin was positive. 
Complement fixation test (CFT)
All BP and control sera (including a negative and a positive 
internal control for each test run) were diluted 1:2 with phospha-
te-buffered saline (PBS), pH 7.4, and incubated on unfixed, 
salt-split, frozen cut, healthy human skin samples for 30 min 
at 37°C. After washing for 3 × 10 min with PBS containing 
0.005% Tween-20, a mixture of freshly taken sera from 3 donors 
without autoimmune disease was prepared as a complement 
source. This serum mixture was incubated on the sections at a 
dilution of 1:5 with barbital buffer (1 mM 5,5-diethyl barbituric 
acid, 2.4 mM sodium 5,5-diethylbarbiturate, 0.3 mM CaCl2, 
1.7 mM MgCl2, 146 mM NaCl; pH 7.2 ± 0.2) for 30 min. After 
washing, polyclonal rabbit anti-human C3 complement anti-
body labelled with fluorescein isothiocyanate (Dako, Glostrup, 
Denmark, #F0201) was incubated at a dilution of 1:100 in PBS 
for 30 min at 37°C in a dark, humid chamber. After the last 
wash, sections were mounted in 2.5% 1,4-diazabicyclooctane, 
0.1% sodium azide, and 10% PBS in glycerine for visualiza-
tion. Positivity was defined as linear deposition of C3 at the 
epidermal side of the basement membrane of the salt-split skin 
(Fig. 1). Evaluation of CFT occurred only if the positive and 
negative control samples were unambiguously positive and 
negative, respectively; otherwise, the test was repeated. The 
sections were analysed by a blinded observer who worked with 
pseudonyms, did not have access to any clinical data or previous 
laboratory results of the patients at the time of evaluation, and 
did not know whether the samples would be included later in 
this study (retrospective study).
It is important to note that the CFT described here is a modi-
fication of the IIF on salt-split-skin, and it is not similar to the 
CFT routinely used in serological diagnostics to detect infec-
tions such as brucellosis or syphilis (Wassermann test) (18, 19). 
In the infectiology, the patients’ sera are first depleted of own 
complement, then standard amounts of the antigen of interest 
and external complement are added, and finally, complement 
fixation is detected by suspension of sheep red blood cells, 
which have been pre-incubated with anti-sheep red blood cell 
antibodies. If complement has been fixed, it will be depleted 
and will not be able to lyse the sheep red blood cells (CFT is 
positive). The CFT described here differs largely because it does 
not depend strongly on antigen or complement quantities (the 
patients’ sera are not depleted of own complement, the amounts 
of external complement and antigen are not standardized), the 
detection occurs by visualizing the C3 molecules fixed to the 
basement membrane of salt-split human skin sections, and 
therefore it can only detect anti-basement membrane autoan-
tibodies leading to a very high specificity. In contrast, false 
positivity of the CFT in the infectiology is relatively common.
Further diagnostic methods
For traditional histology, DIF, IIF, BP180 and BP230 ELISA 
(MBL®), standard clinical laboratory methods were used, as 
detailed elsewhere (7).
Statistics
For comparison of titres, Mann-Whitney’s non-parametric, 
unpaired, 2-tailed test was performed. For comparison of 
sensitivities or specificities, McNemar’s test was performed. 
Sensitivities and specificities, as well as positive and negative 
predictive values, are shown together with their 95% confidence 
intervals (95% CI). GraphPad Prism version 4.03 for Windows, 
GraphPad Software, San Diego, California, USA, or calcula-
tors on the GraphPad homepage (http://www.graphpad.com/
quickcalcs/) were used for statistical calculations. 
RESULTS
Sera from 300 patients with BP (151 males, 149 females) 
with a mean age of 76.9 years (range 8.7–96.4 years) 
were tested with CFT and compared with 136 controls 
(52 males, 84 females) with a mean age of 60.2 years 
(range 16.7–93.0 years). CFT was positive in 215 pa-
tients with BP, thus the sensitivity of the CFT was 71.7%; 
negative results were obtained in 85 patients with BP 
(28.3%). The sensitivities of DIF, BP180, BP230, IIF 
monkey, IIF rabbit, IIF monkey and rabbit oesophagus 
together, and IIF salt-split skin were 91.8%, 71%, 56.4%, 
73.7%, 76.3%, 78% and 72.9%, respectively (Fig. 2, 
Table I). The difference between the sensitivities of 
CFT and BP230 ELISA was significant (p < 0.0001); 
however, there was no significant difference between 
the sensitivities of CFT and any other serological test. 
The titres of BP180 and BP230 autoantibodies detected 
by ELISA were significantly different between patients 
with BP and controls (p < 0.0001).
All control samples were negative for the CFT, thus 
specificity was 100%. Specificities for DIF, BP180, 
BP230, IIF monkey, IIF rabbit, IIF rabbit and mon-
Fig. 1. (A and B) Examples of positive results by complement fixation test 
(CFT). Linear deposition of C3 can be observed at the epidermal side of the 
basement membrane of the healthy, human, salt-split skin (arrows). Detection 
occurred by a polyclonal rabbit anti-human C3 complement antibody labelled 
with fluorescein isothiocyanate (original magnification ×200).
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key oesophagus together, and IIF salt-split skin were 
98.6%, 97.5%, 98.3%, 100%, 98.5%, 98.5% and 100%, 
respectively (Fig. 2, Table I). There was no significant 
difference between the specificities of CFT and any 
other serological test. 
Although the sensitivity of each serological method 
was lower than 80%, the combined sensitivity of BP180, 
BP230 and CFT was 90.7% because the CFT detected 
20 of 46 patients with BP (43.5%) who were serologi-
cally negative for both ELISAs. Upon combination of 
CFT with IIF monkey and rabbit together, sensitivity 
increased to 88.7%, since the CFT identified 31 of 
66 patients with BP (47.0%) who were negative for 
IIF on oesophagus. The combination of CFT with all 
serological assays resulted in a sensitivity of 95.3%, 
because 5 of 14 patients with BP (35.7%) were positive 
for CFT who were serologically negative for all other 
serological assays. All these 5 patients were positive for 
DIF; 1 of them had localized BP on the scalp, the others 
had generalized BP. In addition, CFT diagnosed 7 of 18 
patients with BP (38.9%) in whom DIF was negative. 
DISCUSSION
Complement-fixing (herpes gestationis) factor was 
originally described in 1973 by Provost & Tomasi (20) 
in 2 patients with herpes gestationis in whom CFT 
was positive. In 1976, 2 independent research groups 
demonstrated at the same time that the complement-
fixing factor in herpes gestationis was an IgG that could 
not always be detected by conventional DIF or IIF 
methods, but which activated the classical complement 
pathway (11, 12). CFT is based on a different method 
from any other serological assay and it is designed for 
the detection of low-titre IgG autoantibodies against 
basement membrane autoantigens. Thus, we predicted 
that, in patients with BP who were serologically nega-
tive or had borderline results, small amounts of IgG1, 
IgG2, and/or IgG3 could be detected by CFT. To prove 
our hypothesis, we performed CFT in a large number 
of BP and control sera, and found that, in general, CFT 
was a suitable diagnostic test for BP, with a sensitivity 
of 71.7%, which was not significantly different from 
the sensitivities of most other serological methods. 
Furthermore, CFT showed increased sensitivity in 
combination with other assays, and its combination 
with all investigated serological assays provided a 
sensitivity of 95.3% without loss of specificity. Finally, 
CFT was able to diagnose 30–50% of patients with BP 
who were negative for other serological assays or even 
a combination of assays, thus showing the outstanding 
diagnostic value of this test. 
To our knowledge, the performance of CFT in BP has 
not been investigated in the last 25 years, and previous 
studies have either focused on pemphigoid gestationis 
or included only a few patients with BP. In 1975, Jordon 
Table I. Number of patients, sensitivities, specificities, positive and negative predictive values of all immunopathological assays used in 


















Direct immunofluorescence 220   70 91.8 (87.4–95.1)   98.57 (92.3–100)   99.51 (97.3–100) 79.31 (69.3–87.3)
Indirect immunofluorescence monkey 300 136 73.67 (68.3–78.6) 100 (97.3–100) 100 (98.3–100) 63.26 (56.4–69.7)
Indirect immunofluorescence rabbit 300 136 76.33 (71.1–81.0)   98.53 (94.8–99.8)   99.13 (96.9–99.9) 65.37 (58.4–71.9)
Indirect immunofluorescence monkey+ rabbit 300 136 78.0 (72.9–82.6)   98.53 (94.8–99.8)   99.15 (97.0–99.9) 67.00 (60.0–73.5)
Indirect immunofluorescence salt-split skin 287   58 72.87 (67.3–77.9) 100 (93.8–100) 100 (98.3–100) 42.65 (34.2–51.4)
BP180 ELISA 297 118 71.04 (65.5–76.1)   97.46 (92.8–99.5)   98.60 (96.0–99.7) 57.21 (50.1–64.2)
BP230 ELISA 291 115 56.36 (50.5–62.1)   98.3 (93.9–99.8)   98.80 (95.7–99.9) 47.08 (40.6–53.6)
Complement fixation test 300 136 71.7 (66.2–76.7) 100 (97.3–100) 100 (98.3–100) 61.5 (54.8–68.0)
BP180, BP230: hemidesmosomal antigens that play a role in the attachment of basal keratinocytes to the basement membrane; 95% CI; 95% confidence 
interval; BP: bullous pemphigoid.
Fig. 2. Comparison of sensitivities and specificities of the different 
diagnostic methods for the diagnosis of bullous pemphigoid 
(BP). Patient numbers are detailed in Table I. DIF: direct 
immunofluorescence; IIF: indirect immunofluorescence; CFT: 
complement fixation test; BP180, BP230: hemidesmosomal antigens 
which play a role in the attachment of basal keratinocytes to the 
basement membrane.
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et al. (16) used CFT to study sera from 46 patients with 
BP and found a sensitivity of only 54.3%, although the 
sera were all highly positive for IIF on normal human 
skin (serum dilutions ≥1:320 were positive). In 1990, 
Fuligni et al. (17) examined sera from 15 patients 
with BP who were serologically negative for IIF on 
monkey oesophagus, and found that 5 patients (33%) 
were positive for CFT. In the last 25 years, serological 
diagnostics have improved substantially. Sensitivities 
of all IIF methods have increased and commercial 
ELISAs have been introduced since 1990; nevertheless, 
our data are consistent with those of Fuligni et al. (17) 
with regard to frequent positivity of CFT (47% in our 
patient cohort) in case of negative IIF on (monkey and 
rabbit) oesophagus. No further studies investigating the 
performance of CFT in BP were found in the medical 
literature represented in the PubMed library.
The sensitivities of the methods other than CFT were 
significantly lower compared with data published by 
a number of authors, but they are consistent with the 
results of some other studies. As already discussed in 
detail in our previous study (7), this difference is proba-
bly due to the varying study design of previous studies, 
mainly the inclusion criteria of the patients, because 
higher sensitivities were found only in studies including 
a low number of patients or testing only IIF-positive 
sera (7). In the present study, we intended to improve 
the sensitivity of BP serology; thus we deliberately 
included negative or borderline-positive sera.
Some sera included in our study were negative for 
both BP230 and BP180, and thus a diagnosis different 
from BP (such as epidermolysis bullosa acquisita or 
p200 pemphigoid) might be possible. We reviewed 
these 38 sera thoroughly and found that, in 26, IIF on 
salt-split skin was also negative, and the DIF was not 
performed on a salt-split sample. CFT was positive and 
negative in 11 and 15 (42% and 58%) of these 26 sera, 
respectively; all the positive samples showed C3 fluores-
cence on the epidermal side of the salt-split skin, thus 
false positivity of CFT could be excluded. However, a 
possibly wrong diagnosis of the 15 negative sera may 
have influenced the sensitivity of the CFT. Nevertheless, 
as the expected frequency of diseases showing identical 
results to those of BP using DIF and/or IIF is less than 
10% of all BP cases, we can state that wrong diagnosis 
may have occurred only in 1–4 patients (0.3–1.3% of 
all patients with BP), which is a too small number to 
significantly modify our results. Such a small variation 
in the results is already considered by the limits of the 
95% CIs (Table I).
The combination of CFT with any assay resulted 
in increased sensitivity, and had the advantage of an 
extremely high specificity for BP. Thus, in laboratories 
in which IIF (on monkey oesophagus or salt-split skin) 
is a screening method, CFT may be used as a secon-
dary, additional test on sera with negative IIF results, 
as it increases sensitivity by approximately 10–15%, 
detecting approximately 50% of BP autoantibodies 
that are undetectable by IIF. As BP sera were positive 
by CFT, even in some cases that were negative for all 
other assays, and CFT positivity has a very high positive 
predictive value, CFT may also serve as a confirmatory 
test of borderline or ambiguous results. In addition, CFT 
is a relatively cheap method, although it is laborious 
and requires some experience in evaluation of salt-split 
skin samples.
Our study was somewhat limited by its retrospective 
nature and the lack of precise data about disease severity 
and extent. Consequently, the correlation of diagnostic 
data with clinical manifestations was not possible. An-
other limitation was the exclusion of patients having 
non-BP bullous autoimmune skin diseases as control 
subjects; therefore, specificity of CFT could not be 
examined accurately. However, pemphigus sera are not 
expected to fix complement at the basement membrane, 
IgA autoantibodies in linear IgA bullous dermatosis do 
not fix complement, and some other pemphigoid-like 
diseases, such as epidermolysis bullosa acquisita, can 
be clearly distinguished by the dermal fluorescence on 
salt-split skin. Consequently, it is not expected that a 
relevant number of sera from patients having non-BP 
bullous autoimmune skin diseases would be false-
positive in the CFT.
In conclusion, CFT is useful for the diagnosis of 
not only pemphigoid gestationis but also BP, and we 
recommend its use as a secondary test in patients who 
are either negative or borderline-positive for other 
serological assays or DIF. Given its high specificity, a 
positive result has a very high positive predictive value; 
false positive results are not expected. Thus it is espe-
cially useful for confirming borderline positive results 
and for the diagnosis of serologically challenging cases.
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